Integrating kidney function assessment into the clinical interpretation of plasma Alzheimer's disease biomarkers
Year: 2025
Type: editorial
Abstract: As plasma biomarkers like p-tau217 move towards clinical use in Alzheimer's disease (AD), it is important to understand how kidney function may influence their accuracy. Even mild chronic kidney disease (CKD) can alter biomarker levels, potentially impacting test performance. While accounting for renal function may improve specificity, it could reduce sensitivity without greatly changing overall diagnostic accuracy. Most studies focus on mild CKD, leaving gaps in understanding severe CKD-especially in real-world settings like primary care. Including renal indices such as eGFR in diagnostic models could help improve interpretation and minimize misclassification in older adults, where CKD is common.
Source: Journal of Alzheimer s Disease
Institutions: University of Gothenburg, University of Wisconsin–Madison, Sahlgrenska University Hospital, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London, Indian Institute of Science Bangalore, University of Arizona, Banner Sun Health Research Institute, Banner Alzheimer’s Institute
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4414083703